Calyxt

92 articles about Calyxt

• Calyxt Announces Stockholder Approval of Merger With Cibus

  5/19/2023

  Calyxt, Inc. announced the results of the special meeting of its stockholders held on May 18, 2023.

• Calyxt Reports First Quarter 2023 Financial Results and Provides Corporate Update

  5/1/2023

  Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced operating and financial results for its first quarter ended March 31, 2023.

• Calyxt Completes One-for-Ten Reverse Stock Split

  4/24/2023

  Calyxt, Inc. announced that it has completed the previously announced reverse stock split of Calyxt's common stock, par value $0.0001 per share, at a ratio of 1-for-10.

• Calyxt, Inc. Announces Effectiveness of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLC

  4/18/2023

  Calyxt, Inc., a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, announced that the registration statement on Form S-4, initially filed with the U.S. Securities and Exchange Commission by Calyxt on February 14, 2023, and amended on April 14, 2023, has been declared effective by the SEC.

• Calyxt Announces Effective Date of Reverse Stock Split

  4/7/2023

  Calyxt, Inc. (Nasdaq: CLXT) ("Calyxt" or the "Company") today announced that it will proceed with the 1-for-10 reverse stock split previously approved by the Company's shareholders at the annual meeting of shareholders on June 1, 2022. 

• Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update

  3/6/2023

  Cellectis S.A. announced today that Calyxt, Inc. today announced operating and financial results for its fourth quarter ended December 31, 2022.

• Calyxt Reports Fourth Quarter 2022 Financial Results and Provides Corporate Update

  3/2/2023

  Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced operating and financial results for its fourth quarter ended December 31, 2022.

• Calyxt, Inc. Announces its Filing of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLC

  2/15/2023

  Calyxt, Inc., a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, announced that Calyxt has filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission on February 14, 2023.

• Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company

  1/17/2023

  Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction.

• Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement

  1/17/2023

  Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (“Calyxt”), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the “Merger Agreement”), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction.

• Top 10 Pharma Company Reduces Drug Wastage through Adoption of Calyx IRT Medication Pooling

  11/22/2022

  Calyx announced that a Top 10 pharmaceutical company is leveraging medication pooling, an advanced inventory management strategy available through Calyx IRT, to improve drug distribution efficiencies and reduce drug wastage in an ongoing, global clinical development program.

• Calyxt Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil

  11/18/2022

  Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biology company announced today that it has successfully completed the first phase in its research collaboration agreement with a leading global food ingredient manufacturer based in Asia to develop an improved soybean capable of producing an oil as a commercial alternative to palm oil.

• Calyxt Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/3/2022

  Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced operating and financial results for its third quarter ended September 30, 2022.

• Calyxt Announces Agreement with Evologic Technologies to Scale Production of its Plant-based Ingredients

  10/6/2022

  Calyxt, Inc. announced that it has signed an agreement with its first manufacturing partner, Evologic Technologies GmbH, to further develop and scale Calyxt's proprietary Plant Cell Matrix™ technology platform.

• Calyxt, Inc. Exploring Strategic Alternatives

  9/22/2022

  Calyxt, Inc. (NASDAQ: CLXT) ("Calyxt"), a plant-based synthetic biology company, today announced that its Board of Directors is evaluating potential strategic alternatives to maximize shareholder value.

• Calyxt to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  9/7/2022

  Calyxt, Inc., a plant-based synthetic biology company, announced that Michael A. Carr, President and Chief Executive Officer, and Bill Koschak, Chief Financial Officer, will present at the H.C Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.

• Calyxt Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  8/4/2022

  Calyxt, Inc., a plant-based synthetic biology company, announced financial results for its second quarter ended June 30, 2022.

• Calyxt to Present at the Canaccord Genuity 42nd Annual Growth Conference

  7/28/2022

  Calyxt, Inc., a plant-based synthetic biology company, announced that Michael A. Carr, Chief Executive Officer, and Bill Koschak, Chief Financial Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference taking place August 8-11, 2022.

• Calyxt to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time

  7/21/2022

  Calyxt, Inc.  (Nasdaq: CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, August 4, 2022 , at 4:30 p.m. Eastern Time to discuss results for the second quarter ended June 30, 2022.

• Calyxt Reports First Quarter 2022 Financial Results

  5/5/2022

  Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced financial results for its first quarter ended March 31, 2022.